HDAC9 and Merkel cell skin cancer: Since the ultimate goal of our studies was to establish a therapeutic approach for MCC, we used a clinically relevant concentration, i.e. concentrations attained in patients treated with the FDA approved HDAC inhibitor vorinostat (SAHA, ZolinzaTM)28.